| Cat.No. | Name | Information |
|---|---|---|
| M1988 | Dabrafenib | Dabrafenib (free base) (GSK2118436A) is a V600 mutant BRAF-specific inhibitor. |
| M3026 | Sorafenib (BAY 43-9006) | Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. |
| M1774 | PLX-4720 | PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively. |
| M1761 | Vemurafenib (PLX4032) | Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy. |
| M2319 | AZ628 | AZ628 is a potent inhibitor for wild-type CRAF and BRAF V600E with IC50 of 29 nM and 34 nM, respectively. |
| M1855 | Dabrafenib Mesylate | Dabrafenib (GSK2118436) is a selective, orally bioavailable inhibitor of Mutant B-raf (BRAF) protein kinase with potential antineoplastic activity. |
| M30788 | KG5 | KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities. |
| M29356 | Raf inhibitor 2 | Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research. |
| M28168 | HG6-64-1 | HG6-64-1 is a potent and selective B-Raf inhibitor, with an IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells. |
| M27869 | CCT241161 | CCT241161 is an orally active pan-RAF inhibitor with IC50s of 3, 6, 10, 15 and 30 nM for LCK, CRAF, SRC, V600E-BRAF and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity. |
| M27818 | Takeda-6D | Takeda-6D (compound 6d) is an orally active and potent BRAF/VEGFR2 inhibitor, with IC50 values of 7.0 and 2.2 nM, respectively. Takeda-6D shows antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells.Takeda-6D shows significant suppression of ERK1/2 phosphorylation. Takeda-6D shows antitumor activity. |
| M21520 | Vemurafenib-d5 | Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. |
| M21513 | Vemurafenib-d7 | Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. Vemurafenib can induce autophagy. |
| M21135 | GNE-9815 | GNE-9815 is one of the most selective kinase inhibitors of RAF, targeting KRAS mutant cancers by combination of drugs. |
| M20688 | B-Raf inhibitor 1 (Compound 13) dihydrochloride | B-Raf inhibitor 1 (Compound 13) is a type IIA Raf inhibitor which bind to the DFG-out conformation with ki of 1 nM,1 nM,and 0.3 nM for B-Raf(WT), B-Raf(V600E) and C-Raf, respectively. |
| M20609 | CCT196969 | CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs. |
| M20334 | WAY-303292 | WAY-303292 is a inhibitor of B-Raf kinase. |
| M20274 | WAY-655860 | WAY-655860 is a inhibitor of B-Raf. |
| M20242 | WAY-635114 | WAY-635114 is a inhibitor of B-Raf kinase. |
| M20241 | WAY-635109 | WAY-635109 is a inhibitor of B-Raf kinase. |
| M20075 | WAY-310819 | WAY-310819 is a B-Raf inhibitor |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
